Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 4.01B |
| Revenue (ttm) | 3.02B |
| Net Income (ttm) | 72.06M |
| Shares Out | 319.00M |
| EPS (ttm) | 0.22 |
| PE Ratio | 57.18 |
| Forward PE | 12.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 558,497 |
| Open | 12.69 |
| Previous Close | 12.57 |
| Day's Range | 12.52 - 12.88 |
| 52-Week Range | 7.02 - 15.42 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 15.60 (+24.01%) |
| Earnings Date | May 1, 2026 |
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and res... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price target is $15.6, which is an increase of 24.01% from the latest price.
News
Amneal Pharmaceuticals Transcript: M&A announcement
The acquisition creates a fully integrated global biosimilars leader, unlocking access to a $300B market opportunity and driving significant financial synergies. The deal is structured for immediate value, with biosimilars expected to contribute $1–1.3B in revenue by 2030.
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion that will expand the drugmaker's biosimilars business.
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“A...
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Grow...
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time,...
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation aerosol an...
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5...
Amneal to Report First Quarter 2026 Results on May 1, 2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 fina...
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assistan...
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
Amneal Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Strong 2025 results set the stage for high single-digit growth in 2026, driven by new launches in generics, injectables, and biosimilars. Specialty products CREXONT and Brekiya are outperforming, while operational shifts in AvKARE boost profitability. International and biosimilars expansion remain key priorities.
Amneal to Participate in Upcoming Investor Conference
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside ch...
Amneal Pharmaceuticals Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 8% revenue growth and 43% adjusted EPS growth, driven by robust performance in Specialty and AvKARE segments. 2026 guidance anticipates continued growth, with new product launches and biosimilars as key drivers.
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per...
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index.
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) w...
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full ...
Amneal Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Focused on becoming the leading U.S. affordable medicines provider by 2030, the company is shifting R&D toward biosimilars and specialty products, driving high single-digit growth. Key launches in complex generics, biosimilars, and branded neurology are fueling revenue and margin expansion.
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease
WASHINGTON--(BUSINESS WIRE)--KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research...
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership...
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approv...
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease
BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase 4 ELEVA...
Amneal Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
The business has shifted focus from oral solids to complex generics, injectables, biosimilars, and specialty products, driving growth and profitability. Key launches like Omnipaque and CREXONT, plus a robust biosimilars pipeline, position the company for strong future performance.
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approv...
Amneal to Participate in Upcoming Investor Conferences
BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financi...